These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 32333216)

  • 1. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
    Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
    Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic therapy, a new player in the field of sarcoma treatment.
    Versleijen-Jonkers YM; Vlenterie M; van de Luijtgaarden AC; van der Graaf WT
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):172-85. PubMed ID: 24613529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
    Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
    BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.
    Zhu B; Li J; Xie Q; Diao L; Gai L; Yang W
    Cancer Biol Ther; 2018 Mar; 19(3):198-204. PubMed ID: 29261005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
    Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
    [No Abstract]   [Full Text] [Related]  

  • 6. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
    Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
    Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-color imaging of angiogenesis and its inhibition in bone and soft tissue sarcoma.
    Hayashi K; Yamauchi K; Yamamoto N; Tsuchiya H; Tomita K; Amoh Y; Hoffman RM; Bouvet M
    J Surg Res; 2007 Jun; 140(2):165-70. PubMed ID: 17418866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
    Fathi Maroufi N; Rashidi MR; Vahedian V; Akbarzadeh M; Fattahi A; Nouri M
    Life Sci; 2020 Jan; 241():117106. PubMed ID: 31786193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiangionic drugs in soft tissue sarcoma].
    Salas S; Huynh T; Deville JL; Duffaud F
    Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
    Weitao Y; Fangxing W; Qiqing C; Jiaqiang W
    Anticancer Drugs; 2019 Aug; 30(7):e0778. PubMed ID: 31305297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced alveolar soft part sarcoma responds to apatinib.
    Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C
    Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib as targeted therapy for sarcoma.
    Li F; Liao Z; Zhang C; Zhao J; Xing R; Teng S; Zhang J; Yang Y; Yang J
    Oncotarget; 2018 May; 9(36):24548-24560. PubMed ID: 29849960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
    Scott AJ; Messersmith WA; Jimeno A
    Drugs Today (Barc); 2015 Apr; 51(4):223-9. PubMed ID: 26020064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibition in non-GIST soft tissue sarcomas.
    Sleijfer S; van der Graaf WT; Blay JY
    Oncologist; 2008 Nov; 13(11):1193-200. PubMed ID: 18987047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.
    Rocchi L; Caraffi S; Perris R; Mangieri D
    Biosci Rep; 2014 Nov; 34(6):e00147. PubMed ID: 25236925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
    Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
    [No Abstract]   [Full Text] [Related]  

  • 18. Significant response to apatinib monotherapy in heavily pretreated advanced HER2-positive breast cancer: a case report and literature review.
    Danni L; Lingyun Z; Jian W; Hongfei Y; Lu X; Peng Y; Xiujuan Q; Yunpeng L; Yuee T
    Cancer Biol Ther; 2020 Jul; 21(7):590-596. PubMed ID: 32233990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib].
    Zhang D; Zhang C; Guo Q
    Zhongguo Fei Ai Za Zhi; 2018 Nov; 21(11):880-884. PubMed ID: 30454552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
    Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
    Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.